Navigation Links
Kensey Nash Announces IDE Submission for Cartilage Repair Device
Date:2/24/2009

EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to study the use of the Company's unique biomaterials technology for treating articular cartilage defects of the knee. The clinical trial will utilize the Company's Cartilage Repair Device, which consists of a proprietary bi-phasic, bioresorbable implant designed to treat chondral lesions.

Articular cartilage injury is commonly encountered in people with active lifestyles. Unlike other tissue types, cartilage possesses a limited capacity to heal. Surgical treatment options available today usually generate a repair tissue that is insufficient in absorbing or distributing loads and is prone to failure. Worldwide, physicians perform approximately one million procedures each year to repair damaged articular cartilage in the knee and a majority of these are repeat procedures, illustrating the ineffectiveness of current therapeutic approaches. Over time, debilitating osteoarthritis may develop in the afflicted joint ultimately requiring partial or total knee replacement. The Company believes that an early and successful treatment of traumatized articular cartilage may prevent the long-term onset of osteoarthritis, and consequently reduce the number of radical knee joint replacement surgeries performed each year.

"Our cartilage repair product team has made great progress in the development of this device over the past few years. Significant preclinical research has been conducted with some of the premier academic institutions in the U.S.," stated Douglas G. Evans, COO of Kensey Nash Corporation. "Our IDE submission for this clinical trial represents an important accomplishment towards achieving full commercializatio
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... U.S. Food and Drug Administration approved a new type 2 ... class of once-a-week injectable drugs that help manage blood sugar ... is a new treatment option, which can be used alone ... levels in the overall management of type 2 diabetes," Dr. ... Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... published today in the online journal PLoS Outbreaks ... West Africa by the end of the month if ... State University and Harvard University researchers also discovered through ... significantly increased in August in Liberia and Guinea, around ... place, indicating that the mass quarantine efforts may have ...
(Date:9/19/2014)... September 19, 2014 Famous Vancouver company, ... that it has now become a one-stop-solution for heating, ... businesses in Vancouver. The company has achieved this status ... to its customers. While there are many companies that ... have a single vendor who can offer all of ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2
... Now that school is back in session,on-line use ... teachers and friends or just play interactive games. ... predator will,use its anonymity to develop trust with a ... quickly," said Dr. Don Bross, Co-director of,The Kempe Center,s ...
... WASHINGTON, Sept. 11 The Substance Abuse ... organizations to,receive the agency,s inaugural Science and ... evidence-based interventions to,prevent and treat mental illnesses ... awards program provides recognition to public sector,organizations ...
... ,Color of Hope, Jewelry Collection Donates 100% of Net Profits to ... ... Paris proudly commemorates,the 10th anniversary of its partnership with The Ovarian ... empowerment,causes. Over the past decade, L,Oreal Paris has offered hope to ...
... Reminder of Need for Genuine Reform -,Nurses Pledge to Continue ... ... Nurses Panel Lauds Guaranteed Healthcare Systems, OAKLAND, Calif., Sept. ... will lead a delegation of several,hundred registered nurses to the ...
... on most prescription drug containers highlight the pharmacys name ... the medication, reports a new study in the September ... The Institute of Medicine estimates that 1.5 million medication ... poor labeling is one cause of the mistakes. While ...
... patients never take these important medications again, study finds ... seniors stop taking medications for chronic health problems such ... spending limits in their Medicare prescription drug plans, new ... research organization the RAND Corporation, also found that many ...
Cached Medicine News:Health News:Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators 2Health News:SAMHSA Announces First Science and Service Award Winners 2Health News:SAMHSA Announces First Science and Service Award Winners 3Health News:SAMHSA Announces First Science and Service Award Winners 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 2Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 3Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 4Health News:L'Oreal Paris Celebrates Ten Years of Hope and Healing 5Health News:September 11th First Responders Lead Emotional Rally at State Capitol Tuesday 2Health News:Prescription labels geared toward pharmacies, not patients 2Health News:Medicare Spending Caps Cause Seniors to Stop Meds 2
Inquire...
... are accurate to 1 mm. In vivo results ... patients encapsulation scar tissue. Encapsulation scar tissue can ... therefore actual projection may vary from patient to ... surgeon with a scalpel or surgical scissors. All ...
... IQmarkTM Diagnostic Workstation Software offers a ... that digitally stores many different diagnostic ... Microsofts open-architecture products in mind, our ... integration (using ActiveX controls), networking, central ...
... engineered to set a new standard for ... enter the patient demographics, select auto report ... based system uses the latest in software ... of the IQmark Holter algorithm. Simple, intuitive ...
Medicine Products: